Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Clovis Oncology, Inc. (NASDAQ: CLVS).

Full DD Report for CLVS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLVS)

Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, as well as trials in progress presentations of Rubraca ® (rucaparib) in multiple solid tumor settings at ASCO Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that seven abstracts highlighti...
Source: Business Wire
Date: May, 16 2018 11:55
Clovis May 2018 Update
Here's a quick figure for what is on everyone's mind: Clovis (Rucaparib) and Tesaro (Zejula) product revenues, image created by Author As can be seen, Tesaro ( TSRO ) still has a strong lead in sales and is growing moderately fast, and indeed faster than Clovis ( CLVS ). While we should ...
Source: SeekingAlpha
Date: May, 16 2018 05:41
CORRECTING and REPLACING Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018
Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time (instead of Thursday, May 17, 2018 at 10:00 AM Pacific Time). The corrected release reads: CLOVIS ONCOLOGY TO PRESENT AT THE BANK OF AMERICA MERRI...
Source: Business Wire
Date: May, 09 2018 16:05
Consolidated Research: 2018 Summary Expectations for Catalent, MGIC Investment, United Rentals, Clovis Oncology, Pure Storage, and Chipotle Mexican Grill - Fundamental Analysis, Key Performance Indications
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catalent, Inc. (NYSE:CTLT), MGIC Investment Corporation (NYSE:MTG), United...
Source: GlobeNewswire
Date: May, 09 2018 07:35
Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q1 2018 Results - Earnings Call Transcript
About: Clovis Oncology (CLVS) Q1 2018 Results Earnings Conference Call May 08, 2018, 04:30 PM ET Executives Breanna Burkart - VP of IR and Corporate Communications Daniel Muehl - SVP of Finance and Principal Financial & Accounting Officer Lindsey Rolfe - Chief Medical Officer...
Source: SeekingAlpha
Date: May, 08 2018 23:02
Clovis Oncology misses by $0.18, beats on revenue
Clovis Oncology (NASDAQ: CLVS ): Q1 EPS of -$1.54 misses by $0.18 . More news on: Clovis Oncology, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:17
Clovis Oncology Announces First Quarter 2018 Operating Results
$18.5M in Rubraca ® sales for the first quarter of 2018, based on limited third-line BRCA-mutant ovarian cancer treatment label in U.S. All-comers and earlier-line ovarian cancer maintenance treatment indication approved in U.S. on April 6, 2018 CHMP adopted positive...
Source: Business Wire
Date: May, 08 2018 16:05
Notable earnings after Tuesday's close
AAOI , AAXN , AGTC , ALEX , AMBC , APEI , ARNA , AVD , BECN , BIO , BOJA , BW , CA , CERS , CHUY , CISN , CLVS , CORT , CSOD , CTRE , CUTR , CVG , DEI , DIOD , DIS , DVAX , DXPE , EA , ECPG , EPR , ESE , ESIO , ETSY , EVC , EXTR , FANG , FARM , FOSL , ...
Source: SeekingAlpha
Date: May, 07 2018 17:35
Clovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the companyȁ...
Source: Business Wire
Date: April, 24 2018 16:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1752.0052.0153.9051.251,537,973
2017-02-0362.6464.2964.4861.502,813,363
2017-02-0265.5565.3666.3864.75011,319,405
2017-02-0165.0065.1867.1663.352,332,009
2017-01-3161.6164.8064.9060.362,311,855

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1366,934166,14940.2855Short
2018-08-1087,976189,84746.3405Short
2018-08-09201,332723,38727.8319Cover
2018-08-08304,668527,14157.7963Short
2018-08-07236,170366,19764.4926Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLVS.


About Clovis Oncology, Inc. (NASDAQ: CLVS)

Logo for Clovis Oncology, Inc. (NASDAQ: CLVS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CLVS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 19 2018
      Free Writing Prospectus
      Filing Type: FWPFiling Source: edgar
      Filing Date: April, 17 2018
      Free Writing Prospectus
      Filing Type: FWPFiling Source: edgar
      Filing Date: April, 17 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: April, 17 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: April, 17 2018
      Post-effective Amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR
      Filing Type: POSASRFiling Source: edgar
      Filing Date: April, 16 2018

       

       


      Daily Technical Chart for (NASDAQ: CLVS)

      Daily Technical Chart for (NASDAQ: CLVS)


      Stay tuned for daily updates and more on (NASDAQ: CLVS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CLVS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLVS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CLVS and does not buy, sell, or trade any shares of CLVS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/